Helus Pharma Updates Clinical Anxiety Treatment Pipeline

The company announced a shift in its HLP004 development strategy alongside an update on its HLP003 clinical program.

Updated on Oct. 21, 2026 in Mental Health

Bold flat-color editorial illustration of a medical vial and molecular structure, representing pharmaceutical research and clinical anxiety treatment strategy. — Helus Pharma is transitioning its HLP004 anxiety treatment to a monotherapy approach following the completion of its HLP003 Phase 3 study. AI Illustration. Upload story photo >

Live Poll

Do you trust information provided by pharmaceutical companies regarding upcoming clinical trial results?

Helus Pharma announced at an investor presentation that it is shifting the development strategy for its HLP004 treatment from an adjunctive therapy to a monotherapy for generalized anxiety disorder. This follows the completion of enrollment for its HLP003 APPROACH Phase 3 study earlier this year.

Why it matters

The company believes that HLP004 monotherapy will address a significant unmet need for patients with generalized anxiety disorder who currently have limited treatment options. The adjustment aims to better position the drug within the competitive landscape of anxiety medications.

The upcoming HLP004 study will evaluate two 30 mg doses in adults with a minimum Hamilton Anxiety Rating Scale score of 20. The company previously enrolled 223 participants in the APPROACH Phase 3 study for HLP003, which currently holds FDA Breakthrough Therapy Designation.

The players

Helus Pharma

A pharmaceutical company with corporate offices in New York and Toronto that focuses on developing treatments for central nervous system disorders.

FDA

The Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals and medical devices in the United States.

The details

The new Phase 2 trial for HLP004 will be a multi-center, randomized, double-blind, placebo-controlled study. Helus Pharma intends to test the treatment as a monotherapy rather than an add-on medication to address existing gaps in current care.

July 2026: Enrollment completed for 223 participants in the APPROACH study.
October 21, 2026: Helus Pharma held an investor presentation.
Q4 2026: Anticipated topline data readout for the HLP003 Phase 3 study.
Q1 2027: Expected initiation of the HLP004 Phase 2 monotherapy study.
2028: Planned filing of a New Drug Application with the FDA for HLP003.

The Big Picture

The clinical progress of HLP003 and the strategic pivot for HLP004 are aligned with the development standards required to maintain an FDA Breakthrough Therapy Designation. This path represents the broader industry move toward specialized, targeted monotherapies for chronic mental health conditions.

The shift toward HLP004 monotherapy could eventually offer a new treatment option for adults struggling with generalized anxiety disorder who may not respond well to existing therapies. Patients should consult with their healthcare providers regarding future clinical trial participation as these programs advance.

The takeaway

The pivot to a monotherapy strategy highlights the industry push to develop more streamlined anxiety treatments. Future updates will be critical in determining whether these new drug candidates meet the necessary efficacy standards for FDA approval.

What happens next

Helus Pharma expects to release HLP003 Phase 3 topline data in Q4 2026, followed by the initiation of the HLP004 Phase 2 study in Q1 2027 and an HLP003 New Drug Application filing in 2028.